Amgen Inc. has joined a long list of pharma companies eager to capitalize on Micromet's BiTE antibody platform, which showed unusual promise in recent Phase II studies. The agreement tallies up to $976 million including an up-front payment of €10 million (US$14 million), plus milestones, royalties and development funding.